The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 1, 2000, Pages 53-57

  Tas, Faruk ^a   Aykan, N Faruk ^a   Aydiner, Adnan ^a   Uygun, Kazim ^a   Basaran, Mert ^a   Camlica, Hakan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Gastric cancer; Prognostic factor; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LACTATE DEHYDROGENASE;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PARTIAL GASTRECTOMY; PROGNOSIS; SPLENECTOMY; STOMACH ADENOCARCINOMA; TOTAL STOMACH RESECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SPLENECTOMY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034083440     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200002000-00015     Document Type: Article

References (24)

1. Wingo P, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 1995;45:8-30.
2. McNeer G, Bowden L, Booher RJ, McPeak CJ. Elective total gastrectomy for cancer of the stomach: end results. Ann Surg 1974;180:252-6.
3. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. Ann Surg 1989;209:162-6.
4. Sugimachi K, Kodama Y, Kumashiro R, Kanematsu T, Shoichi N, Inokuchi K. Critical evaluation of prophylactic splenectomy in total gastrectomy for the stomach cancer. Gan To Kagaku Ryoho 1980;71:704-9.
5. Noguchi Y, Imada T, Matsumoto A. Radical surgery for gastric cancer: a review of the Japanese experience. Cancer 1989;64: 2053-62.
6. Maehara Y, Moriguchi S, Yoshida M, Takahashi I, Korenaga D, Sugimachi K. Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Cancer 1991;67:3006-9.
7. Viste A, Haugstvedt T, Eide GE, Soreide O. Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988;207:7-13.
8. Gunderson L, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operative series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
9. Landry J, Tepper J, Wood W, Moulton E, Koemer F, Sullinger J. Patterns of failure following curative resections of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990;19:1357-62.
10. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-7.
11. Pyrhönen S, Kuitunen T, Kouri M. A randomized, phase III trial comparing fluorouracil, epidoxorubicin, and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer [Abstract]. Ann Oncol 1992;3(suppl 5):12.
12. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
13. Glimelius B, Hoffmann K, Haglund U, et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90.
14. Scheithauer W, Kornek G, Zeh B, et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomised trial [abstract]. In: Program and abstracts of the Second International Conference on Biology, Prevention and Treatment of GI Malignancy: Köln, Germany, 1995:68.
15. Bozzetti F, Bonfanti G, Audisio RA, Doci R, Dossena G, Gennari L, Andreola S. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet 1987;164:151-4.
16. Boddie AW Jr, McMurtrey MJ, Giacco GG, McBride CM. Palliative total gastrectomy and esophagogastrectomy. Cancer 1983;51: 1195-200.
17. Salvon-Harman JC, Nikulasson S, Khettry U, Stone MD, Lavin P. Shifting proportions of gastric adenocarcinoma. Arch Surg 1994; 129:381-8.
18. Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GN. Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol 1992;87:572-9.
19. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sides. Br J Cancer 1990;62:440-3.
20. Maehara Y, Moriguchi S, Kakeji Y, Orita H, Haraguchi M, Korenaga D, Sugimachi K. Prognostic factors in adenocarcinoma in the upper one-third of the stomach. Surg Gynecol Obstet 1991;173:223-6.
21. Ohno S, Tomisaki S, Oiwa H, Sakagushi Y, Ichiyoshi Y, Maehara Y, Sugimashi K. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg 1995;180:577-82.
22. Nanus DM, Kelsen DP, Niedzwiecki D, Chapman D, Brennan M, Cheng E, Melamed M. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J Clin Oncol 1989;7:1105-12.
23. Kodera Y, Yamamura Y, Torii A, et al. The prognostic value of preoperative serum levels of CEA and CA 19-9 in patients with gastric cancer. Am J Gastroenterol 1996;91:49-53.
24. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, Bensted J. The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Eur J Cancer 1996;32A:63-8.